Signatera is the only patient-specific, custom-built
circulating tumor DNA (ctDNA) monitoring assay to
support cancer treatment planning in early- and
late-stage cancers.
Signatera for colorectal cancer (CRC)
The personalized, molecular residual disease (MRD) assessment and surveillance
monitoring tool to guide optimal treatment decision-making.
Review our clinical pipeline with leading institutions and biopharmaceutical
partners, learn more about our registry studies, or contact us for research services.